Updated on 16 October 2012
As well as being synergistic with current approved SOC HCV treatments, preclinical studies have demonstrated that BIT225 also works well in vitro with some polymerase inhibitors, another new drug class in clinical development.
BIT225 is also in development for treatment of HIV, with a phase Ib/2a trial currently in progress. BIT225 offers a unique opportunity for potential use in the HIV/HCV co-infected population. A trial in this patient population is anticipated to commence before the end of 2012.
Get direct access to more such reports. Subscribe to BioSpectrum Bureau 
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
